Biodesix Announces Three Abstracts to Be Presented at ASCO 2023 Annual Meeting
01 6월 2023 - 7:00PM
Business Wire
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic
solutions company with a focus in lung disease, announced today
that three new scientific abstracts will be presented as part of
the 2023 American Society of Clinical Oncology (ASCO) Annual
Meeting including a poster presented by Friends of Cancer Research
(FoCR) featuring genomic data contributed by Biodesix and other
organizations.
This poster highlights long term patient outcomes from the
ctMoniTR Project, a study evaluating the prognostic value of
changes in circulating tumor DNA (ctDNA) in patients treated with
targeted therapies. The new data release indicates that ctDNA shows
promise as an early endpoint to support drug development and
regulatory decision-making.
“We are thrilled to partner with our colleagues in industry,
academia, government and Friends of Cancer Research in contributing
to the new data analysis on ctDNA and outcomes that will be
released at the ASCO 2023 Annual Meeting,” said Gary Pestano, Chief
Development Officer of Biodesix. “ctDNA continues to show promise,
in a range of clinical indications and we are proud to support the
efforts to generate evidence on how it can positively impact
patient lives.”
The other two abstracts showcase new health economic and
outcomes data on the VeriStrat® host immune classifier, part of
IQLung™ personalized lung cancer treatment guidance testing. These
analyses evaluated healthcare resource utilization (HCRU) and
healthcare costs in patients with non-small cell lung cancer
(NSCLC) classified by the test. The VeriStrat test is a novel
predictive and prognostic blood-based host immune classifier that
stratifies immune checkpoint inhibition (ICI) treatment response in
patients with advanced NSCLC. Prior studies have shown that
patients classified by the test as host immune classifier hot
(HIC-Hot), also known as VeriStrat Good, had better outcomes, on
average living 2-3 times longer when compared to patients
classified as host immune classifier cold (HIC-Cold), also known as
VeriStrat Poor.
The first poster, titled “Real-world healthcare resource
utilization amongst non-small cell lung cancer (NSCLC) patients
tested with a host immune classifier (HIC),” shows that patients
with HIC-C classifications have higher HCRU during their lung
cancer diagnosis. However, patients with an HIC-H classification
had higher HCRU with respect to prescriptions and emergency room
visits. The second poster, titled “Real-world healthcare costs
amongst non-small cell lung cancer (NSCLC) patients tested with a
host immune classifier (HIC),” shows that patients with HIC-C
classifications had significantly higher total medical costs
through the course of lung cancer diagnosis and treatment than
those with an HIC-H classification.
These data reinforce the utility of the VeriStrat test in
guiding treatment decisions and suggest that earlier identification
of the VeriStrat classification may help identify patients with
NSCLC most likely to benefit from additional health system
navigation support.
About Biodesix
Biodesix is a leading data-driven diagnostic solutions company
with a focus in lung disease. The Company develops diagnostic tests
addressing important clinical questions by combining multi-omics
through the power of artificial intelligence. Biodesix offers five
Medicare-covered tests for patients with lung diseases. The blood
based Nodify Lung® nodule risk assessment testing strategy,
consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates
the risk of malignancy in pulmonary nodules, enabling physicians to
better triage patients to the most appropriate course of action.
The blood based IQLung™ strategy for lung cancer patients
integrates the GeneStrat® targeted ddPCR™ test, the GeneStrat NGS™
test and the VeriStrat® test to support treatment decisions across
all stages of lung cancer with results in an average of two to
three business days, expediting time to treatment. Biodesix also
leverages the proprietary and advanced Diagnostic Cortex® AI
(Artificial Intelligence) platform, to collaborate with many of the
world’s leading biotechnology and pharmaceutical companies to solve
complex diagnostic challenges in lung disease. For more information
about Biodesix, visit biodesix.com.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that
involve substantial risks and uncertainties for purposes of the
safe harbor provided by the Private Securities Litigation Reform
Act of 1995. All statements contained in this press release other
than statements of historical fact, are forward-looking statements.
The words “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,”
“opportunity,” “goals,” or “should,” and similar expressions are
intended to identify forward-looking statements. Such statements
are based on management’s current expectations and involve risks
and uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors. Biodesix has based these
forward-looking statements largely on its current expectations and
projections about future events and trends. These forward-looking
statements are subject to a number of risks, uncertainties, and
assumptions. Forward-looking statements may include information
concerning the impact of the COVID-19 pandemic on Biodesix and its
operations, its possible or assumed future results of operations,
including descriptions of its revenues, profitability, outlook, and
overall business strategy. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified. The Company's ability to continue as a
going concern could cause actual results to differ materially from
those contemplated in this press release and additionally, other
factors that could cause actual results to differ materially from
those contemplated in this press release can be found in the Risk
Factors section of Biodesix’s most recent annual report on Form
10-K, filed March 14, 2022 or subsequent quarterly reports on Form
10-Q during 2022, if applicable. Biodesix undertakes no obligation
to revise or publicly release the results of any revision to such
forward-looking statements, except as required by law. Given these
risks and uncertainties, readers are cautioned not to place undue
reliance on such forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230601005387/en/
Media: Robbie Lunt robbie.lunt@biodesix.com
1-866-432-5930
Investors: Chris Brinzey chris.brinzey@westwicke.com
(339) 970-2843
Biodesix (NASDAQ:BDSX)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Biodesix (NASDAQ:BDSX)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024